Novel Potassium Binders for Hyperkalemia and Optimization of RAAS Inhibitor Therapy in CKD or Heart Failure: A Systematic Review and Meta-analysis

Newer potassium-lowering medicines helped patients stay on full doses of heart- and kidney-protective RAAS-inhibitor drugs by controlling high potassium, with the biggest benefit in chronic kidney disease.